NSAID Toxicity Risk Assessed in Cancer Patients
Researchers evaluated major toxicity risks for cancer patients in palliative care settings.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you trust predictive risk models to guide your personal medical decisions?
Researchers at the University of California, San Diego, recently presented retrospective findings on the risk of major toxicity from nonsteroidal anti-inflammatory drugs (NSAIDs) in palliative care patients. These analyses, presented in September 2026, aimed to clarify safety profiles for patients often balancing multiple health conditions.
Why it matters
This research addresses the current lack of high-quality evidence regarding NSAID safety in oncology, helping providers better manage pain while minimizing complications. By identifying hypertension and statin use as predictive factors, the study assists clinicians in tailoring care decisions for vulnerable patient populations.
In retrospective studies of 228 outpatients and 574 inpatients at Jacobs Medical Center, researchers estimated 1-year major toxicity probabilities. Findings showed significant variation, with 11.2% risk for inpatient NSAID users, while hypertension and statin use emerged as key predictive markers.
The players
University of California, San Diego
A public research university conducting clinical studies on pain management and oncology outcomes.
Jacobs Medical Center
An academic medical center that served as the primary setting for the inpatient retrospective study.
The details
Researchers developed predictive models to estimate the risk and severity of toxicity in patients undergoing palliative care consultations. The study identified that patients with existing comorbidities like hypertension or those on concurrent statin therapy face higher risk profiles when using these medications. These findings provide a framework for clinicians to assess the safety of NSAID use alongside standard cancer care protocols.
Timeline
Inpatient data were collected between January 2022 and July 2023.
Outpatient data were gathered from January 2023 to March 2024.
Findings were presented at the PAINWeek conference held September 8-11, 2026.
Health Landscape
This research builds upon established palliative care research protocols at the University of California, San Diego to refine clinical safety standards. It marks an update to historical risk assessments for common medications used during cancer treatment.
If you or a family member are undergoing cancer treatment, it is worth discussing the risks and benefits of all medications, including over-the-counter NSAIDs, with your oncology team. Be sure to report any existing conditions like hypertension or concurrent medication use to your doctor.
The takeaway
Understanding the toxicity profile of common pain relievers is vital for managing chronic symptoms in complex cancer cases. Maintain a complete list of all medications and supplements to review with your healthcare provider during your next consultation.
Further reading
For broader guidance on managing symptoms, visit the Cancer section.
Source note: This article includes information reported by Clinical Advisor.
Live Poll
Do you trust predictive risk models to guide your personal medical decisions?
